{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T12:13:33Z","timestamp":1788783213254,"version":"build-2803163510"},"reference-count":39,"publisher":"European Respiratory Society (ERS)","issue":"5","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2026,3,13]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Sarcoidosis is a systemic granulomatous disease with highly variable clinical manifestations and organ involvement. Symptoms are often unspecific or absent and may not reflect true inflammatory burden, increasing the risk of delayed detection of organ damage. Reliable assessment of disease activity is therefore essential for treatment guidance. We aimed to investigate the correlation and predictive performance of circulating biomarkers with systemic inflammatory activity as assessed by\n                      <jats:sup>18<\/jats:sup>\n                      F-fluorodeoxyglucose (\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG) positron emission tomography-computed tomography (PET-CT), exploring whether a biomarker-based approach could substitute more resource-intensive imaging.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a retrospective cohort study including 180 patients with systemic sarcoidosis who underwent paired\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET-CT and blood sampling (n=770). Systemic biomarkers including tumour necrosis factor-\u03b1 (TNF-\u03b1), soluble interleukin-2 receptor (sIL-2R), neopterin, angiotensin-converting enzyme (ACE) activity, C-reactive protein (CRP), calciuria and lymphocytopenia were assessed for their association with PET-based inflammatory activity. Variance and correlation analyses as well as receiver operating characteristic curves were used to evaluate diagnostic performance.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      TNF-\u03b1, sIL-2R and neopterin consistently showed significant correlation with PET activity already for moderate inflammatory activity (activity-quartile 2\u20133\n                      <jats:italic>versus<\/jats:italic>\n                      inactive: p&lt;0.001), with TNF-\u03b1 showing the best predictive ability, though overall degree of correlation remained moderate (Pearson's r&lt;0.5; area under the curve: 0.63\u20130.68). Traditional biomarkers such as ACE activity and CRP only showed significant differences at the highest quartile of PET activity (activity-quartile 4\n                      <jats:italic>versus<\/jats:italic>\n                      inactive p&lt;0.001 and p=0.005, respectively). While biomarker correlations were evident for pulmonary and nodal inflammation, weak to no association was found for PET-assessed cardiac activity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Immunological biomarkers such as TNF-\u03b1, sIL-2R and neopterin outperform traditional markers such as CRP and ACE activity, and should be considered in the assessment of systemic sarcoidosis activity at diagnosis and follow-up. Since no biomarker was able to predict cardiac inflammatory activity, imaging techniques such as magnetic resonance imaging and\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET remain central for diagnosis and exclusion of cardiac sarcoidosis.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/23120541.01414-2025","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T17:00:26Z","timestamp":1776358826000},"page":"01414-2025","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunological biomarkers predict pulmonary and nodal, but not cardiac positron emission tomography-assessed sarcoidosis activity"],"prefix":"10.1183","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7591-3885","authenticated-orcid":false,"given":"Roberto","family":"Colli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melina","family":"Stuessi-Helbling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Himmelmann-Wildschuetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2158-2321","authenticated-orcid":false,"given":"Christian","family":"Clarenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronny Ralf","family":"Buechel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9958-0724","authenticated-orcid":false,"given":"Sonja","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Frischknecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"2026090704551606000_12.5.01414-2025.1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-019-0096-x","article-title":"Sarcoidosis","volume":"5","author":"Grunewald","year":"2019","journal-title":"Nat Rev Dis Primer"},{"key":"2026090704551606000_12.5.01414-2025.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2101555"},{"key":"2026090704551606000_12.5.01414-2025.3","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1007\/s12350-018-01582-y","article-title":"Diagnostic performance of F-18 FDG PET for detection of cardiac sarcoidosis; a systematic review and meta-analysis","volume":"27","author":"Kim","year":"2020","journal-title":"J Nucl Cardiol"},{"key":"2026090704551606000_12.5.01414-2025.4","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1007\/s00330-024-10949-4","article-title":"Meta-analysis of [18F]FDG-PET\/CT in pulmonary sarcoidosis","volume":"35","author":"Donnelly","year":"2025","journal-title":"Eur Radiol"},{"key":"2026090704551606000_12.5.01414-2025.5","doi-asserted-by":"crossref","first-page":"1286684","DOI":"10.3389\/fimmu.2023.1286684","article-title":"Assessment of treatment response in cardiac sarcoidosis based on myocardial 18F-FDG uptake","volume":"14","author":"Frischknecht","year":"2023","journal-title":"Front Immunol"},{"key":"2026090704551606000_12.5.01414-2025.6","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2021.06.008"},{"key":"2026090704551606000_12.5.01414-2025.7","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.0954-6820.1979.tb13507.x","article-title":"Prognostic significance of lymphopenia in sarcoidosis","volume":"206","author":"Selroos","year":"1979","journal-title":"Acta Med Scand"},{"key":"2026090704551606000_12.5.01414-2025.8","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2015-307455"},{"key":"2026090704551606000_12.5.01414-2025.9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0009088"},{"key":"2026090704551606000_12.5.01414-2025.10","doi-asserted-by":"publisher","DOI":"10.1373\/49.9.1510"},{"key":"2026090704551606000_12.5.01414-2025.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2007.03.002"},{"key":"2026090704551606000_12.5.01414-2025.12","doi-asserted-by":"publisher","DOI":"10.1378\/chest.124.1.186"},{"key":"2026090704551606000_12.5.01414-2025.13","doi-asserted-by":"publisher","DOI":"10.1378\/chest.98.5.1125"},{"key":"2026090704551606000_12.5.01414-2025.14","doi-asserted-by":"publisher","DOI":"10.1536\/ihj.17-695"},{"key":"2026090704551606000_12.5.01414-2025.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2013.07.010"},{"key":"2026090704551606000_12.5.01414-2025.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2008.10.007"},{"key":"2026090704551606000_12.5.01414-2025.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2008.03.004"},{"key":"2026090704551606000_12.5.01414-2025.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-5231(05)70421-4"},{"key":"2026090704551606000_12.5.01414-2025.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2011.08.012"},{"key":"2026090704551606000_12.5.01414-2025.20","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(75)90395-2"},{"key":"2026090704551606000_12.5.01414-2025.21","first-page":"131","article-title":"Role of serum angiotensin converting enzyme in sarcoidosis","volume":"48","author":"Khan","year":"1998","journal-title":"J Pak Med Assoc"},{"key":"2026090704551606000_12.5.01414-2025.22","doi-asserted-by":"crossref","first-page":"568020","DOI":"10.3389\/fmed.2020.568020","article-title":"Hypercalciuria in sarcoidosis: a specific biomarker with clinical utility","volume":"7","author":"Cameli","year":"2020","journal-title":"Front Med"},{"key":"2026090704551606000_12.5.01414-2025.23","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s40620-022-01360-7","article-title":"Hypercalciuria may predict better response to immunosuppressive therapy in renal sarcoidosis: a case series","volume":"36","author":"Zhao","year":"2023","journal-title":"J Nephrol"},{"key":"2026090704551606000_12.5.01414-2025.24","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-19-0508"},{"key":"2026090704551606000_12.5.01414-2025.25","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/92.2.103"},{"key":"2026090704551606000_12.5.01414-2025.26","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-005-0043-5"},{"key":"2026090704551606000_12.5.01414-2025.27","doi-asserted-by":"crossref","unstructured":"Kobayashi Y , Omote K , Nagai T , et al. Prognostic value of cardiac metabolic activity assessed by 18F-FDG PET in patients with cardiac sarcoidosis. Eur Heart J 2019; 40: Suppl. 1, 2457. doi: 10.1093\/eurheartj\/ehz745.0101","DOI":"10.1093\/eurheartj\/ehz745.0101"},{"key":"2026090704551606000_12.5.01414-2025.28","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0000000000002864"},{"key":"2026090704551606000_12.5.01414-2025.29","doi-asserted-by":"publisher","DOI":"10.1148\/radiology.143.1.7063747"},{"key":"2026090704551606000_12.5.01414-2025.30","doi-asserted-by":"publisher","DOI":"10.2307\/2531595"},{"key":"2026090704551606000_12.5.01414-2025.31","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(96)00236-3"},{"key":"2026090704551606000_12.5.01414-2025.32","first-page":"e2022023","article-title":"Routine laboratory biomarkers as prognostic indicators of cardiac sarcoidosis outcomes","volume":"39","author":"Kolluri","year":"2022","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026090704551606000_12.5.01414-2025.33","doi-asserted-by":"crossref","first-page":"709","DOI":"10.3390\/diagnostics14070709","article-title":"Phenotypes and serum biomarkers in sarcoidosis","volume":"14","author":"Della Zoppa","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"2026090704551606000_12.5.01414-2025.34","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2019.1568240"},{"key":"2026090704551606000_12.5.01414-2025.35","doi-asserted-by":"publisher","DOI":"10.2174\/1389200024605082"},{"key":"2026090704551606000_12.5.01414-2025.36","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000223145.74217.e7"},{"key":"2026090704551606000_12.5.01414-2025.37","first-page":"141","article-title":"Clinical significance of serum and urinary neopterins in patients with chronic renal disease","volume":"36","author":"Godai","year":"1991","journal-title":"Clin Nephrol"},{"key":"2026090704551606000_12.5.01414-2025.38","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00005315"},{"key":"2026090704551606000_12.5.01414-2025.39","doi-asserted-by":"crossref","first-page":"e281","DOI":"10.1210\/clinem\/dgab574","article-title":"Determinants and outcomes associated with urinary calcium excretion in chronic kidney disease","volume":"107","author":"Liu","year":"2022","journal-title":"J Clin Endocrinol Metab"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.01414-2025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:55:25Z","timestamp":1788782125000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.01414-2025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":39,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,9,7]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1183\/23120541.01414-2025"],"URL":"https:\/\/doi.org\/10.1183\/23120541.01414-2025","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]}}}